ORGANIZATION
JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
The Japan Pharmaceutical Manufacturers Association (JPMA) has slapped Takeda Pharmaceutical Chairman Yasuchika Hasegawa with another six-month suspension on his vice president duties at the JPMA after a third party probe confirmed the company’s improper organizational involvement in the CASE-J study.…
To read the full story
Related Article
ORGANIZATION
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





